Endovascular surgery involves minimally invasive procedures that use catheters to deliver therapy and devices to patients with vascular diseases. The demand for endovascular therapies continues to grow dramatically with the global trend towards minimally invasive surgery.
While beneficial, these procedures expose patients and health caregivers to harmful levels of radiation due to the use of X-ray fluoroscopy for navigating through the vascular system. IOPS addresses these challenges by using safe electromagnetic tracking, while improving navigation and simplifying complex procedures.
Outside of the development of our IOPS device, we’re excited to see other advancements in endovascular surgery. Below, you’ll find relevant articles, as well as Centerline Biomedical press releases, to keep you up-to-date on the world of endovascular surgery innovations.
Centerline Biomedical Completes Fifth Preclinical Study
Endovascular navigation startup demonstrates use of navigation system
: As Centerline Biomedical, Inc. prepares to meet with investors, strategic partners and companies in the healthcare industry during the JP Morgan Healthcare Conference, it successfully completed a fifth preclinical study at Cleveland Clinic facilities evaluating its surgical navigation system, IOPS, the Intra-Operative Positioning System. This study was the most noteworthy Centerline study to date, demonstrating ability to track sensorized IOPS instruments precisely and efficiently, with enhanced 3-D visualization, without frequent exposure to cancer-causing ionizing radiation associated with current standard of care.
Centerline Biomedical Named MedTech Innovator Top 50 Showcase Company
We are proud to announce that Centerline Biomedical has been chosen as a MedTech Innovator Top 50 showcase company! The 50 companies
were chosen from nearly 600 applicants to the 2017 MedTech Innovator competition. They will present during 11 interactive sessions on a special stage at the MedTech Innovator Showcase
, an exhibition of the cutting-edge innovations to be presented at The MedTech Conference
Sept. 25 to 27 in San Jose, California.
Centerline Biomedical Furthers Funding Goals with $1.26M Ohio Third Frontier Funding
Endovascular navigation startup receives economic development funding
We are proud to announce that, on March 29th
, 2017, Centerline Biomedical, Inc.
was approved by the Ohio Third Frontier Commission
for a $1.26M Commercial Acceleration Loan Fund (CALF), under the Ohio Third Frontier Program
, managed by the State of Ohio’s Development Services Agency (DSA).
Centerline Biomedical Rounds Up Successful Year With Series A Fundraising
Endovascular navigation startup continues to build momentum with development and funding milestones
Cleveland, Ohio: Surgical navigation startup Centerline Biomedical, Inc. closed a Series A funding round in December 2016. This significant milestone comes on the heels of several preclinical studies and builds upon successful financing and outreach achieved over the course of 2016, driving the company forward in its commercialization mission.
Centerline Biomedical Successfully Completes Next Set of Preclinical Studies
Cleveland, Ohio: Building on a study performed in May, Centerline Biomedical, Inc. successfully completed two additional preclinical studies evaluating its advanced surgical navigation system known as IOPS, the Intra-Operative Positioning System. The studies demonstrated the ability to track navigation of catheters and guidewires precisely, with enhanced 3-D visualization, and without the harmful effects associated with the current standard of care.
Centerline Biomedical Successfully Completes First Preclinical Study
Endovascular Navigation Innovator Centerline Biomedical Successfully Completes First Preclinical Study
In vivo study bolsters commercialization efforts
Cleveland, Ohio: Centerline Biomedical, a Cleveland Clinic spinoff company, successfully completed its first preclinical study evaluating its innovative endovascular navigation technology, IOPS, at the world-renowned Lerner Research Institute on Monday, May 2nd.
HoloLens technology offers opportunity for Centerline Biomedical
A new grant gives Centerline the opportunity to use HoloLens, a mixed-reality device from Microsoft, as an additional tool to be used alongside IOPS. The HoloLens helps the surgeon visualize the patient's anatomy, increasing visibility and navigation. Karl West described it by saying, "It's like having X-ray vision."
Gearing Up to Enter the Market in 2017
The Centerline Biomedical team is excited to continue work gearing up for market entry!
Our innovative IOPS (Intra-Operative Positioning System) device, which provides 3D guidance for endovascular surgery, will allow surgeons to navigate a patient’s arteries in greater detail and with more accuracy than what is offered by the current standard of care.
Learn more about our history and the inspiration behind the IOPS device in this article
CX Acknowledges "huge debt" owed to endovascular pioneers affected by radiation
Since its introduction in the late 80s, endovascular therapy has become increasingly widespread and important. A mini-symposium held at the 2016 Charing Cross Symposium (26-29 April, London, UK), brought to the fore the radiation damage that has occurred to pioneering operators in the field. It also focused on currently available methods to reduce radiation exposure during endovascular procedures.
Do-Better or Do-Over? Cath Lab Safety May Be Ready for a Reboot
At the 2015 Society for Cardiovascular Angiography and Interventions Scientific Sessions, Jonathan J. Rome, MD, director of the catheterization laboratories at The Children’s Hospital of Philadelphia, discussed an issue that affects all interventional cardiologists and radiologists: the long-term toll on our bodies resulting from lifetime exposure to radiation and wearing protective equipment.
Watch 6-minute Documentary on Fluoroscopic Radiation Risks
This video tells the story of one of the world’s most prominent cardiovascular surgeons, Dr. Edward Diethrich, and the career-altering health issues he has faced as a result of chronic, low-level exposure to ionizing radiation through his work.